Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8NEL9

UPID:
DDHD1_HUMAN

ALTERNATIVE NAMES:
DDHD domain-containing protein 1; Phosphatidic acid-preferring phospholipase A1 homolog; Phospholipid sn-1 acylhydrolase

ALTERNATIVE UPACC:
Q8NEL9; G5E9D1; Q8WVH3; Q96LL2; Q9C0F8

BACKGROUND:
The enzyme Phospholipase DDHD1, with alternative names such as Phospholipid sn-1 acylhydrolase, is integral to the hydrolysis of glycerophospholipids, producing free fatty acids and lysophospholipids. It plays a pivotal role in the nervous system by regulating the levels of polyunsaturated phosphatidylinositol and phosphatidylserine lipids, which are crucial for cell biology and mitochondrial dynamics.

THERAPEUTIC SIGNIFICANCE:
Phospholipase DDHD1's dysfunction is associated with Spastic paraplegia 28, highlighting its potential as a therapeutic target. The enzyme's critical role in lipid metabolism and cell biology underscores the importance of further research to explore innovative treatment avenues for related neurodegenerative disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.